Review of Superior Vena Cava Resection in the Management of Benign Disease and Pulmonary or Mediastinal Malignancies
|
|
- Sibyl Parker
- 6 years ago
- Views:
Transcription
1 GENERAL THORACIC Review of Superior Vena Cava Resection in the Management of Benign Disease and Pulmonary or Mediastinal Malignancies Michael Lanuti, MD, Pierre E. De Delva, MD, Henning A. Gaissert, MD, Cameron D. Wright, MD, John C. Wain, MD, James S. Allan, MD, Dean M. Donahue, MD, and Douglas J. Mathisen, MD Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts Background. Obstruction of the superior vena cava (SVC) by tumor or benign disease implies unreconstructable disease and poor outcome. We analyzed the operative results, graft patency, and survival in patients undergoing SVC resection and reconstruction for benign disease and pulmonary or mediastinal malignancy. Methods. Patients undergoing SVC resection from 1997 to 2007 for surgical management of benign and invasive neoplasms were retrospectively reviewed. Results. We identified 19 patients requiring SVC resection. Malignant disease was resected in 17: lung cancer in 9 and mediastinal malignancy in 8. Two patients (10%) with benign processes required reconstruction for chronic SVC syndrome. Ringed Gore-Tex conduit (W. L. Gore and Associates, Flagstaff, AZ) was used for 12 reconstructions (63%) of the SVC, and 7 patients underwent primary closure or autologous pericardial patch repair. Preoperative chemoradiotherapy was administered to 9 patients (53%). There was one perioperative death (5%). Major postoperative morbidities included atrial fibrillation in 5, stroke in 2, respiratory failure in 3, myocardial infarction in 1, and Horner syndrome in 1. Median survival for the entire cohort was 45.5 months (range, 0.2 to 147 months), with a mean follow-up of 45.8 months. Five-year survival probability was 30% for patients with resected lung cancer and 56% for patients with resected anterior mediastinal malignancies. Conclusions. Resection and reconstruction may be safely performed in selected patients for benign and malignant obstruction or infiltration of the SVC. Survival and intermediate-term patency after tubular grafting of the SVC are acceptable. (Ann Thorac Surg 2009;88:392 8) 2009 by The Society of Thoracic Surgeons The superior vena cava (SVC) is susceptible to invasion from tumors arising from the anterior mediastinal compartment, such as thymomas, thymic carcinoma, thyroid neoplasms and germ cell tumors, as well as right-sided pulmonary neoplasms. Extended resection for SVC invasion (T4 disease) of non-small cell lung cancer (NSCLC) and anterior mediastinal neoplasms often evokes controversy about its long-term benefit but has been associated more recently with acceptable morbidity and survival in published series [1, 2]. The reported 5-year survival rate after SVC resection and reconstruction for lung cancer is 21% to 31% [3, 4] and for anterior mediastinal neoplasms is 45% to 53% [5, 6]. With regard to lung cancer, the results of tumors involving the SVC are far better than one would predict with stage IIIB NSCLC, with a historical survival of 6% to 8% [7]. The proposed 2009 revision (7th edition) of the T N M classification of lung cancer by the International Association for the Study of Lung Cancer (IASLC) has Accepted for publication April 16, Presented at the Poster Session of the Forty-fifth Annual Meeting of The Society of Thoracic Surgeons, San Francisco, CA, Jan 26 28, Address correspondence to Dr Lanuti, 55 Fruit St, Blake 1570, Boston, MA 01748; mlanuti@partners.org. taken into account the potential resectability and different prognosis of T4 N0-1 M0 and transferred these tumors to stage IIIA [8]. The feasibility and low morbidity of extended resection for pulmonary or mediastinal tumors infiltrating the SVC are well documented, but the selection of optimal candidates for aggressive resection is less well defined. Although some prognostic factors have been reported [9], ambiguity remains. Completeness of resection, extent of SVC involvement, and the presence of mediastinal lymph node metastases are all regarded as important in the evaluation of these select patients. There is little contention about SVC resection for anterior mediastinal tumors, but SVC resection in the context of NSCLC with nodal metastasis remains controversial. This study evaluates the outcomes of a heterogeneous group of patients undergoing en bloc SVC resection as part of an R0 resection of malignant disease of the lung and anterior mediastinum. Material and Methods This study was approved by the Institutional Review Board (IRB) at the Massachusetts General Hospital. The IRB specifically considered this retrospective records 2009 by The Society of Thoracic Surgeons /09/$36.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg LANUTI ET AL 2009;88:392 8 SVC RESECTION FOR BENIGN AND MALIGNANT DISEASE 393 GENERAL THORACIC Fig 1. (A) Tangential superior vena cava (SVC) resection with primary repair. (B) Patch repair with bovine or autologous pericardium, (C) SVC replacement with ringed polytetrafluoroethylene graft (Gore-Tex) to left brachiocephalic vein. (Reprinted, with permission, from [10] Garcia A, Flores RN. Surgical management of tumors invading the superior vena cava. Ann Thorac Surg 2008;85: ) review, including subject selection and confidentiality, and waived the need for patient consent. Patients The study population included consecutive patients undergoing SVC resection and reconstruction for treatment of benign or malignant disease on the Thoracic Surgery Service at the Massachusetts General Hospital between January 1997 and December Retrospective medical record reviews were performed. The specific objective of the study was to evaluate the outcomes of radical resection for disease involving the SVC. The study included all patients who underwent SVC resection for pulmonary, mediastinal, or thyroid malignancies, as well as 2 patients with SVC syndrome from obstructive benign disease. No patient required extracorporeal bypass to achieve resection. The study was inclusive of all surgical approaches that provided suitable access, including median sternotomy, cervical sternotomy, and thoracotomy. Demographic, preoperative, intraoperative, and outcome measures were recorded. Data were obtained from the medical records, including office records, anesthesia records, and in-hospital records. Preoperative assessment included clinical examination, diagnostic imaging, pulmonary function, quantitative ventilation-perfusion scan (for pneumonectomy), bronchoscopy, and mediastinoscopy in most patients with NSCLC. Aside from diagnostic chest computed tomography, metastatic survey was performed with brain magnetic resonance imaging (MRI), bone scan, and when available beginning in about 2000, whole-body positron emission tomography (PET). Echocardiography was routinely used to fully evaluate biventricular function and rule out severe tricuspid regurgitation. Operative Repair The degree of SVC infiltration dictated the type of resection. Primary repair was achieved in 5 patients when less than 50% of caval circumference was resected. Suture repair was conducted with running polypropylene suture, usually by tangential placement of a partial occlusion clamp. Larger defects were repaired in 2 patients using an autologous pericardial patch (Fig 1A and B). In 12 patients in whom SVC infiltration encompassed more than 50% of the vessel, the SVC was replaced with a ringed polytetrafluoroethylene (PTFE) graft (median size, 14 mm; sometimes reconstructed using technique in Fig 1C). Temporary interruption of flow during prosthetic replacement with proximal and distal caval clamps was managed with intravascular fluid expansion, lower extremity venous access, hyperventilation to reduce vasogenic cerebral edema, reverse Trendelenburg position, and vasoactive agents to elevate cerebral profusion pressure. The graft was introduced onto the operative field. The distal SVC anastomosis was performed first using 4-0 proline suture. This anastomosis is then tested for any leak. The proximal venous anastomosis is subsequently performed, and air was removed from the conduit before tying down the last anastomotic suture. Some resections included the brachiocephalic veins. There was a preference to reconstruct only one of the veins. All patients received intravenous heparin sodium (50 to 100 U/kg) 5 to 10 minutes before vascular occlusion. After intraoperative heparinization, the partial thromboplastin time (PTT) was allowed to normalize without pharmacologic reversal. Patients were selectively transitioned to an antiplatelet agent or Coumadin (Bristol-
3 GENERAL THORACIC 394 LANUTI ET AL Ann Thorac Surg SVC RESECTION FOR BENIGN AND MALIGNANT DISEASE 2009;88:392 8 Table 1. Patient and Operative Characteristics Characteristic Age, mean SD, y Prosthetic graft reconstruction, No. (%) 12 (63) Partial resection, No. (%) 7 (37) Acute graft thrombosis, No. (%) 2 (10) Follow-up, median SD, mon Overall morbidity, No. (%) 12 (63) 30-day mortality, No. (%) 1 (5) Non-small cell lung cancer Survival, median SD, mon year survival, % 30 Anterior mediastinal neoplasms Survival, median SD, mon year survival, % 56 Table 2. Histology of Resected Neoplasms Histology No. (%) Non-small cell lung cancer 9 Adenocarcinoma 3 (33) Adenosquamous cell carcinoma 1 (11) Squamous cell carcinoma 3 (33) Epithelioid hemangioendothelioma 1 (11) Poorly differentiated carcinoma 1 (11) Mediastinal tumors 8 Thyroid carcinoma 3 (38) Thymic carcinoma 3 (38) Germ cell neoplasm 1 (12) Primary adenocarcinoma 1 (12) Benign disease 2 SD standard deviation. Myers Squibb, Princeton, NJ) at the surgeon s discretion. Most patients with a PTFE vascular reconstruction received anticoagulation therapy for a minimum of 3 months. Statistical Analysis Survival curves were constructed using the Kaplan- Meier method and compared with the log-rank test. Survival analyses were calculated with SPSS 14.0 software (SPSS Inc, Chicago, Ill). Comparisons of survival were performed for patients undergoing neoadjuvant therapy, nodal status in resected NSCLC, and tumor location. Results From January 1997 to 2007, 19 patients (10 men) underwent SVC resection for treatment of locally invasive disease. Patients were aged 41 to 82 years (Table 1). Of these, 17 patients (90%) had malignant disease, 1 had an intravascular lipoma associated with SVC syndrome, and another had fibrosing mediastinitis from histoplasmosis. The indication for SVC resection was direct invasion by tumor or relief of SVC obstruction from a malignant or benign process. Complete resection (R0) was achieved in all malignant cases. There were no intraoperative deaths. Resections were for NSCLC in 9 patients (47%), and the remainder were for invasive disease associated with thymic in 3, thyroid in 3, germ cell in 1, and a primary mediastinal neoplasm in 1. Mean follow-up for the entire cohort (excluding benign disease) was months, with a survival probability of 41% at 5 years and 27% at 10 years (Fig 2). In patients with lung cancer, resections were performed through a right thoracotomy. Staging mediastinoscopy was performed in 7 of 9 patients (78%) with lung cancer. Ipsilateral N2 disease was confirmed in 2 of 7 patients and treated with induction chemoradiotherapy. Fig 2. Kaplan-Meier curves show overall survival of 17 patients who underwent superior vena cava resection for malignant disease. Fig 3. Kaplan-Meier curves show comparison of overall survival of 9 patients with resected non-small cell lung cancer (NSCLC, dotted line) and 8 patients with anterior mediastinal tumors (solid line); p
4 Ann Thorac Surg LANUTI ET AL 2009;88:392 8 SVC RESECTION FOR BENIGN AND MALIGNANT DISEASE Fig 4. Kaplan-Meier curves show overall survival of resected lung cancer stratified by nodal T N M stage of N0 (black line), N1 (dotted line), and N2 (dashed line). Surgical staging of the mediastinum was not performed in 2 patients. One patient received preoperative chemoradiotherapy where restaging PET showed no fluorine-18 fluoro-2-deoxy-d-glucose (FDG) activity in the mediastinal nodes. Another patient underwent right carinal pneumonectomy with no FDG activity in the mediastinum save for the tumor itself. Pulmonary resections included right intrapericardial pneumonectomy in 3, right carinal pneumonectomy in 1, right upper lobe sleeve lobectomy in 2, bilobectomy in 1, and middle lobectomy in 1. The histology of the resected tumors is listed in Table 2. One patient had T3 N1 disease with direct extension of hilar lymph nodes abutting the SVC requiring partial resection with primary repair. Metastatic ipsilateral mediastinal lymph node disease (T4 N2) was present in 3 patients, all of whom have died (mean survival, 13.2 months). Pathologic T4 N0 disease was documented in 3 patients, and T4 N1 disease in 1. Median survival for patients with lung cancer undergoing en bloc SVC resection was 21.4 months (range, 4.6 to months), with a 5-year survival probability of 30% (Fig 3). Patients with T N M stage N2 disease had a trend toward worse survival (p 0.089; Fig 4); however, when node-negative resections (N0) were compared with node-positive (N1-2) resections, the survival difference was statistically significant (p 0.040). Median sternotomy was the most common approach to anterior mediastinal tumors. These tumors consisted of Hürthle cell carcinoma, anaplastic thyroid cancer, germ cell neoplasm, thymic carcinoma, and primary mediastinal carcinoma. Median survival for resected neoplasms of the anterior mediastinum was 64.5 months (range, 0.2 to 123 months), with a 5-year survival probability of 56% (Fig 3). Induction chemoradiotherapy was completed in 3 of 9 patients (33%) with NSCLC and in 6 of 8 (75%) with anterior mediastinal malignancy. Adjuvant chemotherapy was administered to 5 of 9 patients (56%) with resected lung cancer. There was no significant survival difference between patients receiving induction chemoradiotherapy and those undergoing primary resection, followed by adjuvant therapy. Partial SVC resection was performed in 7 of 19 patients (37%), and an autologous pericardial patch was used for reconstruction in 2. Ringed PTFE grafts (size range, 8 to 18 mm) were used to reconstruct 12 SVC resections (63%), including ligation of a unilateral brachiocephalic vein in 5 patients. Symptomatic acute thrombosis of the SVC repair occurred in 2 patients (10%) early in the postoperative period (Table 1). One patient underwent SVC embolectomy within 24 hours with no further sequelae, and another patient with a resected intravascular SVC lipoma (primary SVC repair) was treated with anticoagulation, with resolution of upper extremity edema. Twelve patients (63%) were discharged with Coumadin therapy. Two patients had preoperative SVC thrombosis. Bronchial stumps after pneumonectomy were selectively covered with vascularized tissue, including pericardial fat, omental transposition, or intercostal muscle. One postoperative death occurred within 30-days in a patient with anaplastic thyroid cancer who underwent thyroidectomy with right brachiocephalic and partial SVC resection. Major complications in the 19 patients were atrial fibrillation in 5 (26%), respiratory failure in 3 (16%), stroke in 2 (11%), early SVC thrombosis in 2 (11%), and 1 patient (5%) each with Horner syndrome, postoperative myocardial infarction, and acute respiratory distress syndrome. SVC venous occlusion time associated with 12 circumferential resections was 50 minutes or less in all patients, with one exception. The need to replace the SVC was unanticipated preoperatively in one patient, and bleeding during dissection required SVC clamping for a prolonged period. This resulted in bilateral posterior ischemic optic neuropathy. The visual loss eventually improved over many months. Comment 395 The selection of appropriate candidates for extended resection of pulmonary and anterior mediastinal neoplasms involving the SVC remains challenging. Preoperative diagnostic imaging, including fusion CT-PET, CT venography, and gated cardiac MRI, has improved our ability to stage tumors and predict resectable disease. Pathologic staging with mediastinoscopy, endobronchial ultrasound transbronchial lymph node biopsy, or thoracoscopy is paramount in determining a multimodality strategy in these heterogeneous patients. Evidence for improved outcome after extended surgical resection for multistation N2 or bulky ( 2 cm in short-axis diameter) N2 disease in NSCLC is lacking [11], and patients with this stage should be very carefully selected. Earlier studies examining SVC resection for infiltrating malignant disease do not consistently document details of preoper- GENERAL THORACIC
5 GENERAL THORACIC 396 LANUTI ET AL Ann Thorac Surg SVC RESECTION FOR BENIGN AND MALIGNANT DISEASE 2009;88:392 8 ative staging, thus weakening conclusions about nodal disease and outcomes [2, 9, 12]. Although this study has a small sample size and is underpowered for any meaningful statistical analysis, the presence of nodal disease (N1-2) in resected NSCLC was significant (p 0.04) for predicting poor long-term survival compared with node-negative disease (N0). This intuitive observation was corroborated in studies by Dartevelle and colleagues [3] in 1991, Suzuki and colleagues [4] in 2004, and Spaggiari and colleagues [5] in Spaggiari and colleagues reported a 5-year survival of 52% for N0 disease compared with 21% for pathologic N2 disease. In contrast to many of the publications examining extended resection for SVC invasive malignancy, Suzuki and colleagues [4] differentiated 5-year survival with SVC invasion by direct tumor extension (36%) from those with SVC invasion by metastatic lymph nodes (6.6%). This separation may be artificial when induction therapy obscures tissue boundaries as a treatment effect. This distinction was poorly characterized in our patient series, even in the absence of neoadjuvant therapy. Several authors [4, 13, 14] have observed no correlation between T N M nodal status and survival after SVC resection for lung cancer. The conflicting data speak to statistical weakness of small sample sizes. The intraoperative management of SVC resection and reconstruction was relatively uniform in this clinical series. All circumferential SVC resections were performed with ringed PTFE (median size, 14; range, 8 to 18 mm) without a vascular shunt. Size was determined by extent of venous resection and the nature of the distal anastomosis to conform to native brachiocephalic vein or SVC. Other conduit options include tubularized bovine pericardium, spiral saphenous vein graft [15], and more recently, cryopreserved arterial allograft [16]. The overall thrombosis rate of PTFE reconstruction of the SVC has been reported to be 14% to 24% within 3 to 5 years [3, 5]. Most thromboses were observed within the first month of resection and reconstruction. The thrombotic risk is higher when SVC revascularization occurs in the presence of venous collaterals. We observed an overall SVC thrombosis rate of 10% (2 of 19) with a median follow-up of 45 months. Both patients experienced early thrombosis despite anticoagulation within 12 to 24 hours postoperatively. One patient underwent primary suture repair of the SVC and another patient underwent reconstruction with a 12-mm ringed PTFE conduit to the right brachiocephalic vein. The small conduit may have contributed to thrombosis. Although venous Doppler studies were not routine after 30 days, no late symptomatic SVC thrombosis was observed. Coumadin was prescribed to 12 of 19 patients (63%) at discharge, with an average anticoagulation time of 3 to 6 months. Patients who underwent partial resection with suture or pericardial patch repair were often treated solely with enteric-coated aspirin (325 mg) for up to 3 months. Our preference was for unilateral reconstruction of the brachiocephalic veins, with satisfactory long-term patency. In contrast, Shintani and colleagues [17] recommend bilateral brachiocephalic reconstruction due to a thrombosis rate exceeding 50% at 5 to 26 months, particularly with unilateral left venous reconstruction. All patients in the Shintani series received Coumadin anticoagulation for 6 months or longer. Efforts were made to clamp the SVC proximal to the azygous vein to preserve collateral circulation and reduce cerebral edema. Clamping at the cavoatrial junction was routinely avoided to reduce the risk of sinoatrial node injury. Hemodynamic compromise during clamping was uncommon and less concerning in the 2 patients whose SVC was chronically stenosed or occluded before operation. SVC resection and reconstruction was performed after intravenous volume expansion and the use of pharmacologic vasoconstrictors. Although the use of SVC shunts during complete caval occlusion has been described [18], we have not used them. One strategy to reduce caval occlusion time is to perform the distal anastomosis directly to the right atrial appendage by using a Satinsky clamp on the atrium. The proximal venous anastomosis can be per- Table 3. English Literature Review (1994 to 2007) of Patients Undergoing Superior Vena Cava Resection or Reconstruction for Malignant Disease First Author Year No. Lung Cancer, No. N2 Disease, No. (%) Prosthetic Graft, No. Mortality, % 5-Year Survival, % MGH (33) Spaggiari (40) Suzuki (38) Shargall (47) a Spaggiari (50) Spaggiari (33) 3 0 NR Fukuse NR (3 yrs) Dartevelle (33) a Thomas (40) Tsuchiya NR 7 22 NR a Estimated from reported Kaplan-Meier survival curves within the study. MGH Massachusetts General Hospital; NR not reported.
6 Ann Thorac Surg LANUTI ET AL 2009;88:392 8 SVC RESECTION FOR BENIGN AND MALIGNANT DISEASE formed last, thereby reducing central venous clamp time to that necessary for the proximal anastomosis. In most cases, SVC resection and reconstruction was performed first, followed by right-sided bronchopulmonary resections, including pneumonectomy, carinal pneumonectomy, or resections with proximal pulmonary artery invasion. This sequence requires careful attention to avoid bacterial or tumor cell contamination of the prosthetic graft. In the setting of malignancy, an autotransfusion device is not recommended. Venous clamp times were kept at less than 50 minutes, except in 1 patient. Another patient (50-minute SVC clamp time) sustained a transient right hemiparesis on postoperative day 2 while in atrial fibrillation due to an embolic middle cerebral artery occlusion. According to experimental data derived in 1989, 60 minutes of SVC occlusion was physiologically tolerated in a nonhuman primate model [19]; however, Dartevelle and colleagues [18] reported poor tolerance in humans when SVC clamping time exceeded 45 minutes. Our series confirmed a 5-year survival of 30% and 56% for extended resection of lung and anterior mediastinal neoplasms, respectively, found to involve the SVC. This is congruent with previously published series [1 5, 12, 13, 14, 20](Table 3). The extended resections were associated with acceptable morbidity and mortality. Our experience suggests that the need for SVC reconstruction should not be considered a contraindication for resection of a bronchopulmonary or mediastinal neoplasm in an otherwise potentially curable patient, provided a complete resection can be achieved. Financial support for this study was provided by the Division of Thoracic Surgery at the Massachusetts General Hospital. We would like to acknowledge our clinical research coordinators, Sheila Cann, RN, and Diane Davies, RN, for helping to compile the data derived from the Thoracic Surgery database. We would also like to acknowledge Jimmie Honings, MD, for his assistance with the Kaplien-Meier survival analyses. References 1. Spaggiari L, Regnard, J, Magdeleinat P, Jauffret B, Puyo P, Levasseur P. Extended resections for bronchogenic carcinoma invading the superior vena cava system. Ann Thorac Surg 2000;69: Thomas P, Magnan PE, Moulin G, Giudicelli R, Fuentes PE. Extended operation for lung cancer invading the superior vena cava. Eur J Cardiothoracic Surg 1994;8: Dartavelle PG, Chapelier AR, Pastorino U, et al. Long-term follow-up after prosthetic replacement of the superior vena 397 cava combined with resection of mediastinal-pulmonary malignant tumors. J Thorac Cardiovasc Surg 1991;102: Suzuki K, Asamura H, Watanabe S, Tsuchiya R. Combined resection and superior vena cava for lung carcinoma: prognostic significance of patterns of SVC invasion. Ann Thor Surg 2004;784: Spaggiari L, Leo F, Veronesi G, et al. Superior vena cava resection for lung can mediastinal malignancies: a single center experience with 70 cases. Ann Thorac Surg 2007;83: Chen KN, Xu SF, Gu ZD, et al. Surgical treatment of complex malignant anterior medisational tumors invading the superior vena cava. World J Surg 2006;302: Moutain CF. Revisions in the international system for staging lung cancer. Chest 1997;111: Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (7th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2007;28: Spaggiari L, Thomas P, Magdeleinat P, et al. Superior vena cava resection with prosthetic replacement for non-small cell lung: long term results of a multicentric study. Eur J Cardiothorac Surg 2002;21: Garcia A, Flores RM. Surgical management of tumors invading the superior vena cava. Ann Thorac Surg 2008;85: Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW; American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:243 65S. 12. Tsuchiya R, Asamaura H, Kondo H, Goya T, Naruke T. Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg 1994;57: Spaggiari L, Magdeleinat P, Kondo H, et al. Results of superior vena cava resection for lung cancer, analysis of prognostic factors. Lung Cancer 2004;44: Shargall Y, de Perrot M, Keshavjee S, et al. 15 years single center experience with surgical resection of the superior vena cava for non-small cell lung cancer. Lung Cancer 2004;45: Doty DB. Bypass of superior vena cava: six years experience with spiral vein graft for obstruction of superior vena cava due to benign and malignant disease. J Thorac Cardiovasc Surg 1982;833: Gomez-Caro A, Martinez E, Rodriguez A, et al. Cryopreserved arterial allograft reconstruction after excision of thoracic malignancies. Ann Thorac Surg 2008;86: Shintani Y, Ohta M, Minami M, et al. Long-term graft patency after replacement of the brachiocephalic veins combined with resection of mediastinal tumors. J Thorac Cardiovasc Surg 2005;129: Dartevelle P, Macchiarini P, Chapelier A. Technique of superior vena cava resection and reconstruction. Chest Surg Clin N Am 1995;5: Masuda J, Ogata T, Kikuchi K. Physiological changes during temporary occlusion of the SVC in cynomolgus monkeys. Ann Thorac Surg 1989;47: Fukuse T, Wada H, Hitomi S. Extended operation for nonsmall cell lung cancer invading great vessels and left atrium. Eur J. Cardiothorac Surg 1997;11: GENERAL THORACIC INVITED COMMENTARY The article by Lanuti and colleagues [1] is important not only in terms of content but also because it offers further evidence that superior vena cava (SVC) resection is indicated to treat pulmonary and mediastinal malignancies. Technically speaking, the article confirms the feasibility of resection without cardiopulmonary support in all patients if selection is appropriate. I would like to add our personal contribution on a biologic prosthesis we routinely use in all patients undergoing SVC resection. Our first patient with lung cancer to receive a bovine pericardial tube was operated on in He is still alive without any anticoagulant regimen, with a fully patent prosthesis, and no graft calcification. To date, we have used biologic bovine pericardial patch in 8 patients, and 2009 by The Society of Thoracic Surgeons /09/$36.00 Published by Elsevier Inc doi: /j.athoracsur
Lung cancer or primary malignant tumors of the mediastinum
Technique of Superior Vena Cava Resection for Lung Carcinomas David R. Jones, MD Division of Thoracic and Cardiovascular Surgery, Department of Surgery, University of Virginia School of Medicine, Charlottesville,
More informationSuperior vena cava replacement combined with venovenous shunt for lung cancer and thymoma: a case series
Original Article Superior vena cava replacement combined with venovenous shunt for lung cancer and thymoma: a case series Wei Dai 1 *, Jifu Dong 2 *, Hongwei Zhang 2, Xiaojun Yang 1, Qiang Li 1 1 Department
More informationProsthetic Reconstruction of the Superior Vena Cava for Malignant Disease: Surgical Techniques and Outcomes
Prosthetic Reconstruction of the Superior Vena Cava for Malignant Disease: Surgical Techniques and Outcomes Yasuo Sekine, MD, PhD, Hidemi Suzuki, MD, PhD, Yukio Saitoh, MD, PhD, Hironobu Wada, MD, and
More informationSurgery for lung cancer invading the mediastinum
Review Article Surgery for lung cancer invading the mediastinum Adnan M. Al-Ayoubi, Raja M. Flores Department of Thoracic Surgery, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New
More informationSuperior vena cava (SVC) resection and reconstruction in nonsmall cell lung cancer (NSCLC) invasion
Review Article Page 1 of 8 Superior vena cava (SVC) resection and reconstruction in nonsmall cell lung cancer (NSCLC) invasion Pankaj Kumar Garg 1, Sneha Sharma 1, Sugandha Arya 1, Sai Yendamuri 2 1 Department
More informationResults of superior vena cava resection for lung cancer Analysis of prognostic factors
Lung Cancer (2004) 44, 339 346 Results of superior vena cava resection for lung cancer Analysis of prognostic factors Lorenzo Spaggiari a, *, Pierre Magdeleinat b, Haruhiko Kondo c, Pascal Thomas d, Maria
More informationResults of Superior Vena Cava Reconstruction With Externally Stented-Polytetrafluoroethylene Vascular Prostheses
Results of Superior Vena Cava Reconstruction With Externally Stented-Polytetrafluoroethylene Vascular Prostheses Ikenna C. Okereke, MD, Kenneth A. Kesler, MD, Karen M. Rieger, MD, Thomas J. Birdas, MD,
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationThe T4 category of lung cancer is defined by invasion of the
Original Article Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category? Shun-ichi Watanabe, MD,* Hisao Asamura,
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationTranslocation of left inferior lobe pulmonary artery to the pulmonary artery trunk for central type non-small cell lung cancers
Original Article Translocation of left inferior lobe pulmonary artery to the pulmonary artery trunk for central type non-small cell lung cancers Yifeng Sun, Yang Yang, Yong Chen, Xufeng Pan, Yu Yang, Wen
More informationThymic Tumors. Feiran Lou MD. MS. Kings County Hospital Department of Surgery
Thymic Tumors Feiran Lou MD. MS. Kings County Hospital Department of Surgery Case HPI 53 yo man referred from OSH for anterior mediastinal mass. Initially presented with leg weakness and back pain for
More informationLung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany
17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental
More informationLung Cancer Clinical Guidelines: Surgery
Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with
More informationSurvival After Extended Resection for Mediastinal Advanced Lung Cancer: Lessons Learned on 167 Consecutive Cases
Survival After Extended Resection for Mediastinal Advanced Lung Cancer: Lessons Learned on 167 Consecutive Cases Lorenzo Spaggiari, MD, PhD, Adele Tessitore, MD, Monica Casiraghi, MD, Juliana Guarize,
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationRoutine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF)
Routine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF) Abstract The results of 25 cases underwent a pedicled pericardial flap coverage for the bronchial
More informationL cancer-related deaths in Japan. The number of patients
Extended Resection of the Left Atrium, Great Vessels, or Both for Lung Cancer Ryosuke Tsuchiya, MD, Hisao Asamura, MD, Haruhiko Kondo, MD, Tomoyuki Goya, MD, and Tsuguo Naruke, MD Division of Thoracic
More informationCarinal resections. Leonidas Tapias, Michael Lanuti. Clinical vignette
Masters of Cardiothoracic Surgery Carinal resections Leonidas Tapias, Michael Lanuti Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA Correspondence to: Michael Lanuti, MD.
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationPartial anomalous pulmonary venous connection to superior
Cavo-Atrial Anastomosis Technique for Partial Anomalous Pulmonary Venous Connection to the Superior Vena Cava The Warden Procedure Robert A. Gustafson, MD Partial anomalous pulmonary venous connection
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationInduction chemotherapy followed by surgical resection
Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationIndex. Note: Page numbers of article titles are in boldface type
Index Note: Page numbers of article titles are in boldface type A Acute coronary syndrome, perioperative oxygen in, 599 600 Acute lung injury (ALI). See Lung injury and Acute respiratory distress syndrome.
More informationA new approach to left sleeve pneumonectomy: complete VATS left pneumonectomy followed by right thoracotomy for carinal resection and reconstruction
Fujino et al. Surgical Case Reports (2018) 4:91 https://doi.org/10.1186/s40792-018-0496-2 CASE REPORT A new approach to left sleeve pneumonectomy: complete VATS left pneumonectomy followed by right thoracotomy
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationAdvanced Lung Cancer Invading the Left Atrium, Treated with Pneumonectomy Combined with Left Atrium Resection under Cardiopulmonary Bypass
Case Report Advanced Lung Cancer Invading the Left Atrium, Treated with Pneumonectomy Combined with Left Atrium Resection under Cardiopulmonary Bypass Junzo Shimizu, MD, 1 Chikako Ikeda, MD, 1 Yoshihiko
More informationImpact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer
Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram
More informationExtended resection of non-small cell lung cancer invading the left atrium, is it worth the risk?
Review Article Page 1 of 5 Extended resection of non-small cell lung cancer invading the left atrium, is it worth the risk? Geraud Galvaing 1,2, Jean Baptiste Chadeyras 1, Patrick Merle 3, Marie M. Tardy
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationSurgical Treatment of Complex Malignant Anterior Mediastinal Tumors Invading the Superior Vena Cava
Ó 2006 by the Société Internationale de Chirurgie World J Surg (2006) 30: 162 170 Published Online: 20 January 2006 DOI: 10.1007/s00268-005-0009-x Surgical Treatment of Complex Malignant Anterior Mediastinal
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationSurgical Techniques and Results for Partial or Circumferential Sleeve Resection of the Pulmonary Artery for Patients with Non-Small Cell Lung Cancer
Surgical Techniques and Results for Partial or Circumferential Sleeve Resection of the Pulmonary Artery for Patients with Non-Small Cell Lung Cancer Robert J. Cerfolio, MD, and Ayesha S. Bryant, MSPH,
More informationLung Cancer Resection on Cardiopulmonary Bypass. Daniel J. Boffa, MD Yale University
Lung Cancer Resection on Cardiopulmonary Bypass Daniel J. Boffa, MD Yale University None related to talk Disclosures Disclaimers I love operating on CPB Disclaimers I love operating on CPB I avoid it for
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationLeft side sleeves. Domenico Galetta 1, Lorenzo Spaggiari 1,2. Introduction
Review rticle Page 1 of 7 Left side sleeves Domenico Galetta 1, Lorenzo Spaggiari 1,2 1 Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy; 2 University School of Milan, Italy Correspondence
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationSaphenous Vein Autograft Replacement
Saphenous Vein Autograft Replacement of Severe Segmental Coronary Artery Occlusion Operative Technique Rene G. Favaloro, M.D. D irect operation on the coronary artery has been performed in 180 patients
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationVideo-assisted thoracic surgery right upper lobe bronchial sleeve resection
Original Article on Thoracic Surgery Video-assisted thoracic surgery right upper lobe bronchial sleeve resection Qianli Ma, Deruo Liu Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationComparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Junhua Zhang*,
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationTracheal stenosis in infants and children is typically characterized
Slide Tracheoplasty for Congenital Tracheal Stenosis Peter B. Manning, MD Tracheal stenosis in infants and children is typically characterized by the presence of complete cartilaginous tracheal rings and
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationSurgical management of lung cancer
Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary
More informationSpecial Treatment Issues in Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Special Treatment Issues in Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationSatellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer
Satellite Pulmonary Nodule in the Same Lobe (T4N0) Should Not Be Staged as IIIB Non Small Cell Lung Cancer Ayesha S. Bryant, MSPH, MD, Sara J. Pereira, MD, Daniel L. Miller, MD, and Robert James Cerfolio,
More informationSURGICAL TECHNIQUE. Radical treatment for left upper-lobe cancer via complete VATS. Jun Liu, Fei Cui, Shu-Ben Li. Introduction
SURGICAL TECHNIQUE Radical treatment for left upper-lobe cancer via complete VATS Jun Liu, Fei Cui, Shu-Ben Li The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China ABSTRACT KEYWORDS
More informationUniportal video-assisted thoracoscopic sleeve lobectomy and other complex resections
Surgical Technique Uniportal video-assisted thoracoscopic sleeve lobectomy and other complex resections Diego Gonzalez-Rivas,2, Eva Fieira, Maria Delgado, Mercedes de la Torre,2, Lucia Mendez, Ricardo
More informationIn non small cell lung cancer, metastasis to lymph nodes, the N factor, is
Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More informationVideo-Mediastinoscopy Thoracoscopy (VATS)
Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin
More informationMitral valve infective endocarditis (IE) is the most
Mitral Valve Replacement for Infective Endocarditis With Annular Abscess: Annular Reconstruction Gregory J. Bittle, MD, Murtaza Y. Dawood, MD, and James S. Gammie, MD Mitral valve infective endocarditis
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationReconstruction of mediastinal vessels for invasive thymoma: a retrospective analysis of 25 cases
Original Article Reconstruction of mediastinal vessels for invasive thymoma: a retrospective analysis of 25 cases Yifeng Sun 1 *, Chang Gu 1 *, Jianxin Shi 1 *, Wentao Fang 1, Qingquan Luo 2, Dingzhong
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationAlthough the incidence of malignant primary mediastinal
Surgery for Invasive Primary Mediastinal Tumors Emile A. Bacha, MD, Alain R. Chapelier, MD, PhD, Paolo Macchiarini, MD, Elie Fadel, MD, and Philippe G. Dartevelle, MD Department of Thoracic and Vascular
More informationPathologic Characteristics of Resected Squamous Cell Carcinoma of the Trachea: Prognostic Factors Based on an Analysis of 59 Cases
Pathologic Characteristics of Resected Squamous Cell Carcinoma of the Trachea: Prognostic Factors Based on an Analysis of 59 Cases The Harvard community has made this article openly available. Please share
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationLung cancer involving neighboring structures is classified
GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,
More informationCardiac tumors are unusual and cardiac malignancy, usually
Cardiac Autotransplantation Shanda H. Blackmon, MD,* and Michael J. Reardon, MD Cardiac tumors are unusual and cardiac malignancy, usually sarcoma, is a very small subset of these. The literature on cardiac
More informationNode-Negative Non-small Cell Lung Cancer
ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and
More informationPANCREATECTOMY WITH MESENTERIC AND PORTAL VEIN RESECTION FOR BORDERLINE RESECTABLE PANCREATIC CANCER: MULTICENTER STUDY
PROPOSAL: PANCREATECTOMY WITH MESENTERIC AND PORTAL VEIN RESECTION FOR BORDERLINE RESECTABLE PANCREATIC CANCER: MULTICENTER STUDY Pancreatic carcinoma represents the fourth-leading cause of cancer-related
More informationPreoperative Workup for Pulmonary Resection. Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016
Preoperative Workup for Pulmonary Resection Kristen Bridges, M.D. Richmond University Medical Center January 21, 2016 Patient Presentation 50 yo male with 70 pack year smoking history Large R hilar lung
More informationAliu Sanni MD SUNY Downstate Medical Center August 16, 2012
Aliu Sanni MD SUNY Downstate Medical Center August 16, 2012 Case Presentation 60yr old AAF with PMH of CAD s/p PCI 1983, CVA, GERD, HTN presented with retrosternal chest pain on 06/12 Associated dysphagia
More informationKinsing Ko, Thom de Kroon, Najim Kaoui, Bart van Putte, Nabil Saouti. St. Antonius Hospital, Nieuwegein, The Netherlands
Minimal Invasive Mitral Valve Surgery After Previous Sternotomy Without Aortic Clamping: Short- and Long Term Results of a Single Surgeon Single Institution Kinsing Ko, Thom de Kroon, Najim Kaoui, Bart
More informationSir Clement Price Thomas performed the first sleeve lobectomy
Parenchymal-Sparing Procedures in Lung Cancer: Sleeve Resection of the Lung for Proximal Lesions Simon Ashiku, MD, and Malcolm M. DeCamp, Jr., MD Sir Clement Price Thomas performed the first sleeve lobectomy
More informationParenchyma-sparing lung resections are a potential therapeutic
Lung Segmentectomy for Patients with Peripheral T1 Lesions Bryan A. Whitson, MD, Rafael S. Andrade, MD, and Michael A. Maddaus, MD Parenchyma-sparing lung resections are a potential therapeutic option
More information